GlassScriptPhysician profile
Rodney De Guzman
NPI 1730158460
$3,573.05
in general payments reported to CMS, 2019-2025
30 companies · $712 in 2025
The $712 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $227 · 2020: $131 · 2021: $729 · 2022: $351 · 2023: $541 · 2024: $881 · 2025: $712.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,134.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,133.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $398.81 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $366.64 | 2021-2025 | Xifaxan |
| Exact Sciences Corporation | $331.49 | 2023-2025 | Cologuard Collection Kit |
| Abbott Laboratories | $300.00 | 2021 | |
| Sumitomo Pharma America, INC. | $287.23 | 2023-2025 | Gemtesa |
| Novo Nordisk INC | $236.89 | 2023-2025 | Ozempic, Rybelsus |
| Astellas Pharma US INC | $199.94 | 2019-2021 | |
| Collegium Pharmaceutical, INC. | $188.78 | 2020-2025 | Belbuca |
| Kowa Pharmaceuticals America, INC. | $184.94 | 2025 | Zoryve |
| Pfizer INC. | $176.68 | 2019-2025 | |
| Abbvie INC. | $143.48 | 2022 | |
| Amgen INC. | $137.39 | 2024-2025 | Krystexxa, Otezla, Repatha |
| Janssen Pharmaceuticals, INC | $119.16 | 2021-2024 | Xarelto |
| Sunovion Pharmaceuticals INC. | $76.87 | 2019-2022 | |
| Vanda Pharmaceuticals INC. | $61.71 | 2023-2025 | Hetlioz, Fanapt |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Forte Bio-Pharma LLC | $59.14 | 2020-2022 | |
| Lilly USA, LLC | $52.81 | 2019-2023 | Mounjaro |
| Amarin Pharma, INC. | $32.54 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $28.19 | 2020 | |
| Lundbeck LLC | $23.42 | 2025 | Rexulti |
| Sun Pharmaceutical Industries INC. | $23.39 | 2021 | |
| Idorsia Pharmaceuticals US INC | $19.08 | 2023 | Quviviq |
| Esperion Therapeutics, INC. | $19.03 | 2021 | |
| Glaxosmithkline, LLC. | $17.03 | 2022 | |
| Sanofi Pasteur INC. | $16.87 | 2023 | |
| Philips North America LLC | $15.99 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.42 | 2025 | Jascayd |
| Boston Scientific Corporation | $15.40 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $12.55 | 2021 | |
| Allergan, INC. | $12.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rodney De Guzman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.